Live Coverage from AES 2017
Clobazam is currently FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome in children 2 years and older.
The diagnostic tool may be especially useful in cases of nonlesional mesial temporal lobe epilepsy.
Patients with refractory epilepsy who fail to benefit from 2 or more AEDs should be referred to alternative therapies.
Patients who died from suspected SUDEP had extensive damage to areas of the mid-brain and brainstem that control autonomic function.
Continuous Infusion in Refractory Status Epilepticus Linked to Increased Mortality, Longer Hospital Stay
Researchers compared outcomes between patients treated with continuous infusion or repeated doses of nonbenzodiazepine anti-seizure medication.
Cannabidiol Effective for Reducing Drop Seizures in Lennox-Gastaut Syndrome Regardless of Clobazam Use
The study was a post-hoc analysis of responders who were on or off concomitant clobazam.
Patients undergoing treatment for ischemic stroke are at greater risk for seizure development.
Treatment with positive airway pressure may help retain or improve seizure control in patients with epilepsy and obstructive sleep apnea.
Treatment algorithms are needed for patients with epilepsy who present with evidence of bone loss.
Researchers examined whether there are clinical features or treatments associated with neuropsychiatric outcomes in BECTS.
Sign Up for Free e-newsletters
Check out what's trending
Neurology Advisor Articles
- McDonald Criteria Update: Further Distinction Between Relapsing-Remitting, Primary-Progressive MS
- Distinct Clinical Characteristics Associated With Subarachnoid Hemorrhage
- Increased Epilepsy Risk Identified in Multiple Sclerosis
- Magnesium Plus Environmental Enrichment Boosts Cognition, Memory in Alzheimer's Mouse Model
- Prognostic Significance of Weight Loss in Patients With Early Parkinsonism
- Coffee Consumption May Decrease Stroke Risk
- When and How to Approach Driving Cessation in Patients With Dementia
- NBT System Gets FDA Clearance for Depression Treatment
- Erenumab, Fremanezumab Reduce Migraine Frequency, Burden
- Some Antiepileptic Drugs Associated With Increased Risk for Toxic Epidermal Necrolysis
- Deep Brain Stimulation Improves Survival in Parkinson Disease
- Induced Hypertension Does Not Improve Outcomes in Subarachnoid Hemorrhage, Cerebral Ischemia
- Devices for Acute, Preventive Migraine Care Now Available
- Evolocumab FDA Approved for Stroke Prevention in Cardiovascular Disease
- Depression in Parkinson Disease Linked to Impaired White Matter Integrity